National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pegylated liposomal irinotecan (Onivyde®) HTA ID: 20028

Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.

Rapid Review

Commenced Completed Outcome
13/06/2017 13/07/2017 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.

NCPE Assessment Process Completed
Rapid review Re-commissioned 15/06/2020
Rapid review completed 14/07/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegylated liposomal irinotecan compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 14/07/2020
Pre-submission consultation with Applicant 07/09/2020
Full HTA Submission received from Applicant 04/03/2021
Preliminary review sent to Applicant 02/09/2021
NCPE assessment re-commenced 04/10/2021
Factual accuracy check sent to Applicant 20/10/2021
NCPE assessment re-commenced 29/10/2021
NCPE assessment completed 12/11/2021
NCPE assessment outcome The NCPE recommends that peg-IRI + 5FU + LV not be considered for reimbursement*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.